Cargando…
Melittin as a safe compound to BALB/c mice immune system; a tiered approach immunotoxicity screening
BACKGROUND: Maintenance of immune system integrity is a vital requirement to protect human body against pathogens/cancers. Natural compounds have long been used due to their benefits for the immune system. One of which is bee venom that contains a peptide called melittin having antimicrobial and ant...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598946/ https://www.ncbi.nlm.nih.gov/pubmed/37880739 http://dx.doi.org/10.1186/s12906-023-04228-w |
_version_ | 1785125668104699904 |
---|---|
author | Karimi, Gholamreza Fatemi, Sina Memar, Bahram Khorrami, Mohammad-Bagher Amali, Arian Sadeghi, Mahmood Esmaeili, Seyed-Alireza Riahi-Zanjani, Bamdad |
author_facet | Karimi, Gholamreza Fatemi, Sina Memar, Bahram Khorrami, Mohammad-Bagher Amali, Arian Sadeghi, Mahmood Esmaeili, Seyed-Alireza Riahi-Zanjani, Bamdad |
author_sort | Karimi, Gholamreza |
collection | PubMed |
description | BACKGROUND: Maintenance of immune system integrity is a vital requirement to protect human body against pathogens/cancers. Natural compounds have long been used due to their benefits for the immune system. One of which is bee venom that contains a peptide called melittin having antimicrobial and anticancer effects. Since a limited number of studies regarding the effects of melittin on the immune system have been carried out, we aimed to evaluate the effects of melittin on BALB/c mice immune system parameters. METHODS: Female BALB /c mice were treated intraperitoneally (i.p) with 0.75 and 1.5 mg/kg doses of melittin for 14 days (5 doses per week). The negative control group received i.p normal saline whereas the positive controls received i.p 20 mg/kg cyclophosphamide (CYP). Immunological parameters such as hematological parameters, delayed-type hypersensitivity (DTH), hemagglutination titer (HA), spleen cellularity, splenocytes proliferation, as well as spleen and bone marrow histopathological assessment were evaluated. RESULTS: Our findings showed that melittin has no gross pathological effect on the spleen and bone marrow. It was also demonstrated that melittin has no any significant effect on hematological parameters. Melittin did not cause any significant changes to proliferation response of splenocytes to PHA and LPS, spleen cellularity, DTH response, as well as the production of anti-SRBC antibodies. According to our results, melittin at 0.75 and 1.5 mg/kg doses could not induce significant changes on immune parameters and as a result, melittin was found to be safe for the mice immune system. |
format | Online Article Text |
id | pubmed-10598946 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105989462023-10-26 Melittin as a safe compound to BALB/c mice immune system; a tiered approach immunotoxicity screening Karimi, Gholamreza Fatemi, Sina Memar, Bahram Khorrami, Mohammad-Bagher Amali, Arian Sadeghi, Mahmood Esmaeili, Seyed-Alireza Riahi-Zanjani, Bamdad BMC Complement Med Ther Research BACKGROUND: Maintenance of immune system integrity is a vital requirement to protect human body against pathogens/cancers. Natural compounds have long been used due to their benefits for the immune system. One of which is bee venom that contains a peptide called melittin having antimicrobial and anticancer effects. Since a limited number of studies regarding the effects of melittin on the immune system have been carried out, we aimed to evaluate the effects of melittin on BALB/c mice immune system parameters. METHODS: Female BALB /c mice were treated intraperitoneally (i.p) with 0.75 and 1.5 mg/kg doses of melittin for 14 days (5 doses per week). The negative control group received i.p normal saline whereas the positive controls received i.p 20 mg/kg cyclophosphamide (CYP). Immunological parameters such as hematological parameters, delayed-type hypersensitivity (DTH), hemagglutination titer (HA), spleen cellularity, splenocytes proliferation, as well as spleen and bone marrow histopathological assessment were evaluated. RESULTS: Our findings showed that melittin has no gross pathological effect on the spleen and bone marrow. It was also demonstrated that melittin has no any significant effect on hematological parameters. Melittin did not cause any significant changes to proliferation response of splenocytes to PHA and LPS, spleen cellularity, DTH response, as well as the production of anti-SRBC antibodies. According to our results, melittin at 0.75 and 1.5 mg/kg doses could not induce significant changes on immune parameters and as a result, melittin was found to be safe for the mice immune system. BioMed Central 2023-10-25 /pmc/articles/PMC10598946/ /pubmed/37880739 http://dx.doi.org/10.1186/s12906-023-04228-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Karimi, Gholamreza Fatemi, Sina Memar, Bahram Khorrami, Mohammad-Bagher Amali, Arian Sadeghi, Mahmood Esmaeili, Seyed-Alireza Riahi-Zanjani, Bamdad Melittin as a safe compound to BALB/c mice immune system; a tiered approach immunotoxicity screening |
title | Melittin as a safe compound to BALB/c mice immune system; a tiered approach immunotoxicity screening |
title_full | Melittin as a safe compound to BALB/c mice immune system; a tiered approach immunotoxicity screening |
title_fullStr | Melittin as a safe compound to BALB/c mice immune system; a tiered approach immunotoxicity screening |
title_full_unstemmed | Melittin as a safe compound to BALB/c mice immune system; a tiered approach immunotoxicity screening |
title_short | Melittin as a safe compound to BALB/c mice immune system; a tiered approach immunotoxicity screening |
title_sort | melittin as a safe compound to balb/c mice immune system; a tiered approach immunotoxicity screening |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598946/ https://www.ncbi.nlm.nih.gov/pubmed/37880739 http://dx.doi.org/10.1186/s12906-023-04228-w |
work_keys_str_mv | AT karimigholamreza melittinasasafecompoundtobalbcmiceimmunesystematieredapproachimmunotoxicityscreening AT fatemisina melittinasasafecompoundtobalbcmiceimmunesystematieredapproachimmunotoxicityscreening AT memarbahram melittinasasafecompoundtobalbcmiceimmunesystematieredapproachimmunotoxicityscreening AT khorramimohammadbagher melittinasasafecompoundtobalbcmiceimmunesystematieredapproachimmunotoxicityscreening AT amaliarian melittinasasafecompoundtobalbcmiceimmunesystematieredapproachimmunotoxicityscreening AT sadeghimahmood melittinasasafecompoundtobalbcmiceimmunesystematieredapproachimmunotoxicityscreening AT esmaeiliseyedalireza melittinasasafecompoundtobalbcmiceimmunesystematieredapproachimmunotoxicityscreening AT riahizanjanibamdad melittinasasafecompoundtobalbcmiceimmunesystematieredapproachimmunotoxicityscreening |